Clinician's Roundtable

Guest: John Barbieri, MD, MBA, FAAD Patients with psoriasis die about five years younger than those without the condition, and cardiovascular disease is the leading cause of this premature mortality. Tune in to hear Dr. John Barbieri discuss strategies to identify risk factors and improve cardiovascular disease prevention in patients with psoriasis. Dr. Barbieri is an Assistant Professor of Dermatology at Brigham and Women's Hospital at Harvard Medical School in Boston.

Guest: Ina Park, MD The United States has seen its largest increase in syphilis cases in the past five years. And with increases prevalent in every region, along with a shortage of medication, additional surveillance strategies and importation resources are necessary. Dive in for a discussion on the challenges and strategies to combat the spread of syphilis with Dr. Ina Park, Professor of Family Community Medicine at the University of California San Francisco School of Medicine.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Melanie Dispenza, MD The future therapeutic landscape for food allergy prevention is looking clearer as a drug typically used to treat hematologic malignancies has shown to prevent systemic anaphylaxis to allergens and increase patients' tolerance to peanuts. Along with this, other therapies are also in development for allergy treatment. To learn more, join Dr. Charles Turck as he dives deeper into this study and its findings with Dr. Melanie Dispenza, Assistant Professor of Medicine at Johns Hopkins University School of Medicine.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Henry Rosenberg, MD Malignant hyperthermia is an inherited disorder primarily recognized by anesthesia professionals. And since this condition can have significant consequences on a patient’s health, including their likelihood of surviving surgery, it’s important to know how to diagnose and treat malignant hyperthermia emergencies in operating room settings. Join Dr. Charles Turck as he dives deeper into this topic with Dr. Henry Rosenberg, a member of the Board of Directors of the Malignant Hyperthermia Association of the United States.

Host: Charles Flexner, MD Daily oral therapy can have low adherence, which is why the field of long-acting formulations is rapidly advancing. Tune in to hear Dr. Charles Flexner discuss how long-acting regimens can address this problem of adherence and help patients living with HIV, tuberculosis, malaria, and other infectious diseases. Dr. Flexner is a Professor of Medicine of Pharmacology, Molecular Sciences, and International Health at Johns Hopkins University, and he also presented a session on this exact topic at the 2024 Conference on Retroviruses and Opportunistic Infections.

Host: Jennifer Caudle, DO Guest: Sayantani Sindher, MD Recently, Omalizumab was studied in patients due to the avoidance of management and guidance when it comes to treating food allergies in children and adults. According to this doctor, approximately 45 percent of patients seen in his clinic have multi-food allergies that are not being met with current treatment options. So to explain his research, Dr. Jennifer Caudle is joined by Dr. Sayantani Sinder, Clinical Associate Professor of Medicine and Pediatric Allergy and Clinical Immunology Physician at Stanford Healthcare and Stanford Medicine Children’s Health.

Guest: Douglas Jones, MD A recent study was done to show the side effects of diphenhydramine for allergic reactions, and one of the main detriments was that it could impair the patient by making them tired or sleepy. Another finding was that it doesn’t work that quickly, so in turn, giving diphenhydramine in a severe allergic reaction could cause more harm than good. To learn more on what you should know before using diphenhydramine in allergic reaction situations and possible better solutions, tune in with Dr. Douglas Jones, Board-Certified Allergist and Immunologist with the Tanner Clinic in Layton, Utah.

Guest: Gates B. Colbert, MD A class of medications called SGLT2 inhibitors have been proven to make a major difference for patients with chronic kidney disease (CKD) with and without diabetes when added to angiotensin converting enzyme (ACE) and angiotensin receptor blockers (ARB) classes of medications. Several medications that have been well studied and approved by the FDA in the United States have shown progression of not only CKD but also cardiovascular events and overall mortality. To learn more about these medications, join Dr. Gates Colbert, Assistant Clinical Professor of Medicine at Texas A&M College of Medicine, and Nephrologist and Certified Hypertension Specialist at Kidney and Hypertension Associates of Dallas.

Host: Michael Greenberg, MD Guest: Chris Bundy, MD, MPH, FASAM Clinicians experiencing substance abuse disorder (SUD) may have some reluctance about utilizing a Physician Health Program; however, it’s important to know what your resources are in terms of formal treatment and to seek a psychiatrist with addiction specialization. Dive into part two of this discussion to learn more about the valuable resources and programs that can help physicians recover from SUD with Dr. Michael Greenberg and Dr. Chris Bundy, Executive Medical Director of the Washington Physicians Health Program and Clinical Assistant Professor of Psychiatry at the University of Washington School of Medicine.

Host: Ashley Baker, MSN, PMHNP Guest: Chi D. Chu, MD, MAS The National Health and Nutrition Examination Survey found that kidney disease awareness among patients in the U.S. is very low. And alarmingly, the proportion of awareness has not changed much over the 15-year period of this study. To uncover more of the findings and how to improve CKD awareness, tune into this discussion with Psychiatric Nurse Practitioner Ashley Baker as she takes a deep dive with Dr. Chi D. Chu, Assistant Professor of Medicine in the Division of Nephrology at the University of California San Francisco and coauthor of the article published in the American Journal of Kidney Diseases, titled “CKD Awareness Among US Adults by Future Risk of Kidney Failure.